Kestra Advisory Services’s Franklin Genomic Advancements ETF HELX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-1,069
Closed -$38.8K – 3661
2025
Q4
$38.8K Buy
+1,069
New +$37.7K ﹤0.01% 4118

Other funds holding HELX

Kestra Advisory Services's HELX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Franklin Genomic Advancements ETF (HELX) in Q1 2026, closing a stake of 1,069 shares — an estimated $38.8K sold.

Kestra Advisory Services first reported a position in HELX in Q4 2025 and held it in 1 quarter. The position peaked at $38.8K in Q4 2025. 7 funds tracked by Wall St. Rank hold HELX as of Q1 2026.

  • Kestra Advisory Services reported no remaining Franklin Genomic Advancements ETF position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 1,069 Franklin Genomic Advancements ETF shares in Q1 2026, an estimated $38.8K.
  • Kestra Advisory Services first reported a position in Franklin Genomic Advancements ETF in Q4 2025 and held it in 1 quarter.
  • Kestra Advisory Services's Franklin Genomic Advancements ETF position peaked at $38.8K in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.